Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq rise as chips recover, Broadcom gains on Apple deal
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
SurModics (SRDX) PT Raised to $68 at Needham & Company Following Earnings
April 28, 2021 3:59 PM EDTNeedham & Company analyst Mike Matson raised the price target on SurModics (NASDAQ: SRDX) to $68.00 (from $61.00) while maintaining a Buy rating.
The analyst commented, "SRDX F2Q21 revenue and EPS beat consensus. Revenue growth improved to 53.3% in F2Q21 from (1.4%) in... More
SurModics (SRDX) Misses Q2 EPS by 1c, Revenues Beat; Offers FY21 EPS Guidance Below Consensus, FY21 Revs. Mid-Point View Above Consensus
April 28, 2021 7:40 AM EDTSurModics (NASDAQ: SRDX) reported Q2 EPS of $0.62, $0.01 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $35 million versus the consensus estimate of $32.95 million.
Summary of Second Quarter and Recent Highlights
Revenue of $35.0 million, an increase of 53% year-over-yearGAAP EPS of $0.58, non-GAAP EPS of $0.62Successful first patient uses of two Sublime radial access... More